Is the price fair?
What JAZZ's price assumes
Today's price asks for −2.2% free cash flow growth a year; over the last three years Jazz Pharmaceuticals plc delivered −2.1%, less than the record.
2.82
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 9.0%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- −2.2%
Growth the price implies · The price pays for −2.2% free cash flow growth a year for a decade; the business has delivered −2.1% a year over the last three.
- Price / book
- 2.76
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 2.76
- EV / EBIToperating margin −0.85%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 3.61
- Free cash flow, trailing twelve months
- $1.27B
- Market capitalisation
- $14.1B
- 3-year revenue growth
- +5.9%
- 3-year free cash flow growth
- −2.1%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $2.05 |
| Its own P/E history, median | $2.31 |
| Its own P/E history, upper quartile | $2.60 |
| 52-week range | $110.75 – $261.72 |
| Today | $249.44 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.